News
Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...
If you're looking to put cash into two fantastic biotech stocks that Wall Street seems particularly bullish on, there's one ...
We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Regeneron Pharmaceuticals, Inc.
The possibility of bullous pemphigoid was also unlikely, given that the blister was located on "a single distal extremity," the researchers said.
Sanofi immunology and oncology development global therapeutic area head Alyssa Johnsen stated: “Until now, treating bullous pemphigoid was very challenging for elderly patients struggling with ...
Sanofi/Regeneron’s Dupixent granted FDA approval for bullous pemphigoid Around 27,000 adults in the US are living with uncontrolled cases of the chronic skin disease Sanofi and Regeneron’s Dupixent ...
The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid (BP). BP primarily affects elderly patients, and is ...
Sanofi & Regeneron’s Dupixent receives US FDA approval to treat patients with bullous pemphigoid Paris Saturday, June 21, 2025, 12:00 Hrs [IST] The US Food and Drug Administration (FDA) has approved ...
Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal results showing improvements in sustained disease remission and reductions ...
“People affected by bullous pemphigoid endure unrelenting itch and painful blisters that can damage the skin. Until now, these primarily elderly patients have had limited therapeutic options available ...
SNY and REGN's Dupixent gets FDA approval for a rare and chronic skin disease, marking its eighth approved indication for the drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results